Kenneth Mills, President and CEO of Regenxbio Inc (RGNX, Financial), executed a sale of 45,000 shares in the company on December 19, 2023, according to a recent SEC Filing. Regenxbio Inc is a biotechnology company focused on the development, commercialization, and licensing of recombinant viral vectors for use in gene therapy. The company's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, is utilized in a broad range of therapeutic areas including metabolic, neurodegenerative, and retinal diseases.
Over the past year, the insider has sold a total of 45,000 shares and has not made any purchases of the company's stock.
The insider transaction history for Regenxbio Inc indicates a trend of 0 insider buys and 1 insider sell over the past year.
On the date of the insider's recent transaction, shares of Regenxbio Inc were trading at $19.69, resulting in a market capitalization of $811.652 million.
The stock's price of $19.69 compared to the GuruFocus Value (GF Value) of $16.77 suggests a price-to-GF-Value ratio of 1.17, indicating that the stock is Fairly Valued based on its GF Value.
The GF Value is determined by considering historical trading multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on the company's historical returns and growth, and future business performance estimates provided by Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
